Baseline pulmonary hypertension in heart transplant recipients: 9 years of experience at Almazov National Medical Research Centre
Objective: to assess the impact of baseline pulmonary hypertension (PH) on early and long-term outcomes following heart transplantation (HT). Materials and methods. From January 2010 to December 2018, 112 HTs were carried out. Based on right heart catheterization results, all recipients were divided...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov
2020-02-01
|
| Series: | Vestnik Transplantologii i Iskusstvennyh Organov |
| Subjects: | |
| Online Access: | https://journal.transpl.ru/vtio/article/view/1101 |
| _version_ | 1797871935785271296 |
|---|---|
| author | M. A. Simonenko G. V. Nikolayev K. N. Malikov P. A. Fedotov Y. V. Sazonova M. A. Bortsova V. E. Rubinchik A. O. Marichev A. E. Bautin M. Y. Sitnikova M. L. Gordeev M. A. Karpenko |
| author_facet | M. A. Simonenko G. V. Nikolayev K. N. Malikov P. A. Fedotov Y. V. Sazonova M. A. Bortsova V. E. Rubinchik A. O. Marichev A. E. Bautin M. Y. Sitnikova M. L. Gordeev M. A. Karpenko |
| author_sort | M. A. Simonenko |
| collection | DOAJ |
| description | Objective: to assess the impact of baseline pulmonary hypertension (PH) on early and long-term outcomes following heart transplantation (HT). Materials and methods. From January 2010 to December 2018, 112 HTs were carried out. Based on right heart catheterization results, all recipients were divided into 2 groups: Group 1 with PH (n = 76; mean pulmonary arterial pressure (mPAP) ≥25 mm Hg), Group 2 – without PH (n = 36; MPAP <25 mm Hg). The average age of Group 1 patients was 46.4 ± 14.9 years, baseline pulmonary vascular resistance (PVR) was 3.5 ± 1.5 Wood units, PVR after reversion test (nitric oxide – 80 ppm, iloprost 20 μg) – 2.8 ± 1.0 Wood units, systolic PAP (sPAP) – 50.1 ± 13.4 mm Hg. The average age in Group 2 was 47.3 ± 12.2 years, baseline PVR – 2.1 ± 0.8 Wood units, sPAP – 27.4 ± 5.3 mm Hg. The dynamics in indicators of early postoperative period (duration of mechanical ventilatory support, use of vasodilators and inotropic support and the length of stay in intensive care unit (ICU), 30-day mortality) and long-term post-HT echocardiography results were assessed. Results. Due to acute right-ventricular failure (RVF) developing after heart transplantation, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) was done in 8 patients (11%) from Group 1 and one patient (3%) from Group 2. Presence of PH did not affect duration of mechanical ventilatory support, inotropic support, and length of stay in ICU. Levosimendan therapy in the early postoperative period was more often performed in Group 1 (n = 29) than in Group 2 (n = 6) (p = 0.048). Nitric oxide inhalation was also more often administered in Group 1 (n = 54); Group 2 (n = 7), (p = 0.003). Sildenafil therapy after HT was comparable in both groups Group 1 (n = 25); Group 2 (n = 6), (p = 0.048). In early post-HT stages, 14 patients died, 30-day mortality was comparable in both groups (p = 0.12). Six months after HT, no differences were found in the sPAP (p = 0.21) and PVR (p = 0.07) levels. Conclusion. Patients with baseline PH after HT have a more severe early postoperative period, including a higher RVF incidence, with the need for ECMO implantation. A PVR level >3.5 Wood units is not a threshold for HT. Patients with baseline PVR >3.5 Wood units following HT show comparable results with patients without baseline PH. This allows such patients (baseline PVR >3.5 Wood units) to be considered for inclusion in the heart transplant waiting list. In addition, 30-day mortality and duration of mechanical ventilatory support after HT in patients with and without baseline PH did not differ. Regardless of the baseline level of sPAP and PVR, all patients showed improvement in these parameters after HT. Six months after HT, no differences were found in sPAP and PVR levels in the patients, regardless of whether there was baseline PH or not. |
| first_indexed | 2024-04-10T00:51:59Z |
| format | Article |
| id | doaj.art-76d32067b11c4f07ad1045d230cfa82d |
| institution | Directory Open Access Journal |
| issn | 1995-1191 |
| language | Russian |
| last_indexed | 2024-04-10T00:51:59Z |
| publishDate | 2020-02-01 |
| publisher | Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov |
| record_format | Article |
| series | Vestnik Transplantologii i Iskusstvennyh Organov |
| spelling | doaj.art-76d32067b11c4f07ad1045d230cfa82d2023-03-13T10:37:26ZrusFederal Research Center of Transplantology and Artificial Organs named after V.I.ShumakovVestnik Transplantologii i Iskusstvennyh Organov1995-11912020-02-0121471310.15825/1995-1191-2019-4-7-13820Baseline pulmonary hypertension in heart transplant recipients: 9 years of experience at Almazov National Medical Research CentreM. A. Simonenko0G. V. Nikolayev1K. N. Malikov2P. A. Fedotov3Y. V. Sazonova4M. A. Bortsova5V. E. Rubinchik6A. O. Marichev7A. E. Bautin8M. Y. Sitnikova9M. L. Gordeev10M. A. Karpenko11Almazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreObjective: to assess the impact of baseline pulmonary hypertension (PH) on early and long-term outcomes following heart transplantation (HT). Materials and methods. From January 2010 to December 2018, 112 HTs were carried out. Based on right heart catheterization results, all recipients were divided into 2 groups: Group 1 with PH (n = 76; mean pulmonary arterial pressure (mPAP) ≥25 mm Hg), Group 2 – without PH (n = 36; MPAP <25 mm Hg). The average age of Group 1 patients was 46.4 ± 14.9 years, baseline pulmonary vascular resistance (PVR) was 3.5 ± 1.5 Wood units, PVR after reversion test (nitric oxide – 80 ppm, iloprost 20 μg) – 2.8 ± 1.0 Wood units, systolic PAP (sPAP) – 50.1 ± 13.4 mm Hg. The average age in Group 2 was 47.3 ± 12.2 years, baseline PVR – 2.1 ± 0.8 Wood units, sPAP – 27.4 ± 5.3 mm Hg. The dynamics in indicators of early postoperative period (duration of mechanical ventilatory support, use of vasodilators and inotropic support and the length of stay in intensive care unit (ICU), 30-day mortality) and long-term post-HT echocardiography results were assessed. Results. Due to acute right-ventricular failure (RVF) developing after heart transplantation, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) was done in 8 patients (11%) from Group 1 and one patient (3%) from Group 2. Presence of PH did not affect duration of mechanical ventilatory support, inotropic support, and length of stay in ICU. Levosimendan therapy in the early postoperative period was more often performed in Group 1 (n = 29) than in Group 2 (n = 6) (p = 0.048). Nitric oxide inhalation was also more often administered in Group 1 (n = 54); Group 2 (n = 7), (p = 0.003). Sildenafil therapy after HT was comparable in both groups Group 1 (n = 25); Group 2 (n = 6), (p = 0.048). In early post-HT stages, 14 patients died, 30-day mortality was comparable in both groups (p = 0.12). Six months after HT, no differences were found in the sPAP (p = 0.21) and PVR (p = 0.07) levels. Conclusion. Patients with baseline PH after HT have a more severe early postoperative period, including a higher RVF incidence, with the need for ECMO implantation. A PVR level >3.5 Wood units is not a threshold for HT. Patients with baseline PVR >3.5 Wood units following HT show comparable results with patients without baseline PH. This allows such patients (baseline PVR >3.5 Wood units) to be considered for inclusion in the heart transplant waiting list. In addition, 30-day mortality and duration of mechanical ventilatory support after HT in patients with and without baseline PH did not differ. Regardless of the baseline level of sPAP and PVR, all patients showed improvement in these parameters after HT. Six months after HT, no differences were found in sPAP and PVR levels in the patients, regardless of whether there was baseline PH or not.https://journal.transpl.ru/vtio/article/view/1101heart transplantationheart failurepulmonary hypertensionphpulmonary artery pressurepappulmonary vascular resistancepvrvasodilators |
| spellingShingle | M. A. Simonenko G. V. Nikolayev K. N. Malikov P. A. Fedotov Y. V. Sazonova M. A. Bortsova V. E. Rubinchik A. O. Marichev A. E. Bautin M. Y. Sitnikova M. L. Gordeev M. A. Karpenko Baseline pulmonary hypertension in heart transplant recipients: 9 years of experience at Almazov National Medical Research Centre Vestnik Transplantologii i Iskusstvennyh Organov heart transplantation heart failure pulmonary hypertension ph pulmonary artery pressure pap pulmonary vascular resistance pvr vasodilators |
| title | Baseline pulmonary hypertension in heart transplant recipients: 9 years of experience at Almazov National Medical Research Centre |
| title_full | Baseline pulmonary hypertension in heart transplant recipients: 9 years of experience at Almazov National Medical Research Centre |
| title_fullStr | Baseline pulmonary hypertension in heart transplant recipients: 9 years of experience at Almazov National Medical Research Centre |
| title_full_unstemmed | Baseline pulmonary hypertension in heart transplant recipients: 9 years of experience at Almazov National Medical Research Centre |
| title_short | Baseline pulmonary hypertension in heart transplant recipients: 9 years of experience at Almazov National Medical Research Centre |
| title_sort | baseline pulmonary hypertension in heart transplant recipients 9 years of experience at almazov national medical research centre |
| topic | heart transplantation heart failure pulmonary hypertension ph pulmonary artery pressure pap pulmonary vascular resistance pvr vasodilators |
| url | https://journal.transpl.ru/vtio/article/view/1101 |
| work_keys_str_mv | AT masimonenko baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT gvnikolayev baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT knmalikov baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT pafedotov baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT yvsazonova baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT mabortsova baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT verubinchik baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT aomarichev baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT aebautin baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT mysitnikova baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT mlgordeev baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre AT makarpenko baselinepulmonaryhypertensioninhearttransplantrecipients9yearsofexperienceatalmazovnationalmedicalresearchcentre |